Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
motilitone + pantoprazole
- Development stage
- Unknown
- Lead developer
- Dong-A ST
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Motilitone + pantoprazole is a **combination therapy** consisting of motilitone (DA-9701), a novel prokinetic agent derived from plant extracts, and pantoprazole, a proton pump inhibitor. Motilitone is formulated from Corydalis tuber and Pharbitis semen and acts by accelerating gastric emptying, promoting gastric accommodation, and modulating visceral hypersensitivity through antagonism at 5-hydroxytryptamine (5-HT3) and dopamine D2 receptors, and agonism at the 5-HT4 receptor. Pantoprazole suppresses gastric acid secretion by selectively inhibiting the H+/K+ ATPase in the gastric parietal cells. This combination is investigated and used for the treatment of functional dyspepsia. Clinical studies show no significant additive effect of the combination over monotherapy of either component in terms of symptom improvement or quality of life scores for functional dyspepsia[1][2][4].
- Brand names
- MotilitoneProtonix
- Other names
- motilitone + pantoprazole
02
Targets
HTR3A (5-hydroxytryptamine receptor 3A)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))DRD2 (Dopamine D2 Receptor)ATP4A (Potassium–transporting ATPase alpha chain 1)HTR4 (5-Hydroxytryptamine receptor 4)
Beyond the preview
Go deeper on motilitone + pantoprazole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on motilitone + pantoprazole.